[{"id":"818c72a5-92a4-43b8-8e83-ad27609f899b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05667506","created_at":"2022-12-28T16:01:43.670Z","updated_at":"2025-02-25T15:27:48.147Z","phase":"Phase 1/2","brief_title":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","source_id_and_acronym":"NCT05667506","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/07/2023","start_date":" 02/07/2023","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-10"},{"id":"48054460-bb4c-4bdd-a42b-f1e76f7803ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04586478","created_at":"2021-01-18T21:52:51.200Z","updated_at":"2025-02-25T16:32:17.231Z","phase":"Phase 2","brief_title":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04586478","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-07"},{"id":"94c71a13-e74f-49dc-a1f8-7d536a6dd6ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684147","created_at":"2021-01-19T20:47:16.231Z","updated_at":"2024-07-02T16:34:27.675Z","phase":"Phase 2","brief_title":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04684147","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 09/22/2022","primary_completion_date":" 09/22/2022","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-10"},{"id":"0e218db0-7dc6-48c1-8a84-60806551e530","acronym":"","url":"https://clinicaltrials.gov/study/NCT04690192","created_at":"2021-02-03T10:56:52.668Z","updated_at":"2024-07-02T16:35:14.757Z","phase":"Phase 1/2","brief_title":"CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04690192","lead_sponsor":"Zou Dehui","biomarkers":" BCL6","pipe":" | ","alterations":" BCL6 rearrangement","tags":["BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • melphalan • busulfan • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-15"},{"id":"b48e675a-8f57-4222-bd60-102284af62b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04232826","created_at":"2021-01-18T20:35:26.256Z","updated_at":"2024-07-02T16:35:52.149Z","phase":"Phase 1","brief_title":"A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04232826","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" PD-L1 • BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["PD-L1 • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2023-03-28"},{"id":"b8f8e1df-6280-40dd-b3b3-7fe8152ea138","acronym":"","url":"https://clinicaltrials.gov/study/NCT04230473","created_at":"2021-01-18T20:34:53.938Z","updated_at":"2024-07-02T16:35:52.094Z","phase":"Phase 1","brief_title":"A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04230473","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 03/13/2020","start_date":" 03/13/2020","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2023-03-28"},{"id":"03b35f16-d501-472b-8e72-f8828b4fc9bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04011293","created_at":"2021-01-18T19:42:25.117Z","updated_at":"2024-07-02T16:36:58.292Z","phase":"Phase 1","brief_title":"A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04011293","lead_sponsor":"Shandong University","biomarkers":" TP53 • CD19","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • CD19 positive • CD19 expression • CD20 negative","tags":["TP53 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • CD19 positive • CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yorwida (inaticabtagene autoleucel)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2019-07-08"}]